Biorem Inc (BRM) AI Stock Analysis

• Market Cap: C$28.56M
• Dividend Yield: N/A
• Average Volume (3M): 45.95K
• Price to Earnings (P/E): 9.2
• Beta (1Y): 0.27
• Revenue Growth: 48.69%
• EPS Growth: 39.18%
• Country: CA
• Employees: 57
• Sector: Utilities
• Sector Strength: 92
• Industry: Industrial - Pollution & Treatment Controls
• EPS (TTM): 0.01
• Shares Outstanding: 16,137,438
• 10 Day Avg. Volume: 25,323
• 30 Day Avg. Volume: 45,952
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Biorem Inc's overall stock score is supported primarily by its strong financial performance, robust revenue growth, and solid cash flow generation. Despite the positive financials, technical indicators show neutral to bearish trends, which temper enthusiasm. The valuation suggests potential undervaluation, but the absence of earnings call insights and dividend yield factors limit the potential upside. Corporate events, while positive, are already reflected in the financial assessments.

Biorem Inc Business Overview & Revenue Model

Company Description

BioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems. In addition, it offers biological processes and testing services; media sampling and analysis; system review and inspections; and media replacements and spare parts. The company operates in Canada, the United States, China, and internationally. BioRem Inc. was founded in 1990 and is headquartered in Puslinch, Canada.

How the Company Makes Money

Biorem Inc generates revenue primarily through the sale and installation of its air emissions control systems. The company offers a range of products designed to address specific air quality issues, from small-scale solutions for localized odor control to large, complex systems for industrial applications. Revenue streams include direct sales of equipment, installation services, and ongoing maintenance and support contracts. Additionally, Biorem may engage in partnerships with engineering firms, municipalities, and industrial companies to deliver customized solutions, contributing to its earnings. The company also invests in research and development to innovate and improve its product offerings, ensuring continued demand and market competitiveness.

Biorem Inc Financial Statement Overview

Summary

Biorem Inc has shown remarkable financial improvement across all verticals. The income statement reveals strong growth and profitability with a 48.67% revenue increase. The balance sheet indicates a solid financial position with a debt-to-equity ratio of 0.33. Cash flow metrics demonstrate effective cash management with positive free cash flow and strong conversion of income to cash.

Income Statement

Biorem Inc has demonstrated strong revenue growth with a significant increase of 48.67% in 2024 compared to the previous year. The gross profit margin stands at 26.87%, reflecting efficient cost management. The net profit margin also improved to 8.13%, indicating enhanced profitability. Both EBIT and EBITDA margins show positive trends, at 11.61% and 12.87% respectively, highlighting operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is 0.33, indicating a healthy leverage position. Return on equity has improved to 28.65%, showcasing effective utilization of shareholder funds. The equity ratio is 37.26%, which suggests a stable capital structure with a good portion of assets financed by shareholders' equity.

Cash Flow

Biorem Inc's free cash flow growth rate is robust, reflecting a turnaround from negative to positive free cash flow. The operating cash flow to net income ratio of 1.21 indicates strong cash generation relative to net income, while the free cash flow to net income ratio of 1.09 further confirms solid cash flow health.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
25.17M	28.86M	24.48M	24.38M	20.65M
	Gross Profit
7.02M	8.76M	6.24M	7.02M	4.86M
	EBIT
3.06M	2.64M	2.07M	2.72M	-1.02M
	EBITDA
3.45M	2.99M	2.68M	3.07M	-814.16K
	Net Income Common Stockholders
2.18M	1.61M	1.30M	2.09M	-1.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.29M	3.78M	4.47M	8.87M	6.47M
	Total Assets
24.08M	20.73M	19.17M	21.95M	17.63M
	Total Debt
4.19M	4.75M	5.67M	828.17K	96.81K
	Net Debt
1.89M	971.14K	1.19M	-8.04M	-6.37M
	Total Liabilities
17.36M	16.21M	17.20M	8.43M	5.90M
	Stockholders Equity
6.72M	4.52M	1.96M	13.52M	11.72M
Cash Flow		Free Cash Flow
-62.84K	1.24M	3.71M	2.99M	2.39M
	Operating Cash Flow
490.03K	1.44M	3.78M	3.34M	2.53M
	Investing Cash Flow
-552.87K	-203.29K	-75.98K	-342.40K	-135.23K
	Financing Cash Flow
-1.33M	-951.80K	-7.56M	-199.74K	-109.36K

Biorem Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BRM, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 1.91, below the 50-day MA of 2.20, and below the 200-day MA of 2.54, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 35.15 is Neutral, neither overbought nor oversold. The STOCH value of 12.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BRM.

Biorem Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BRM	68 Neutral	C$28.56M	9.18	35.13%	―	48.69%	39.18%
Sector *	63 Neutral	$8.50B	10.80	5.35%	4.36%	3.58%	-11.46%
TMG	63 Neutral	C$18.18M	116.67	4.63%	―	14.78%	-90.82%
GRN	58 Neutral	C$14.90M	―	-5.60%	―	-10.37%	95.22%
WATR	47 Neutral	C$4.58M	―	-143.77%	―	-49.88%	-266.67%
SHRC	43 Neutral	C$15.18M	―	-272.36%	―	-13.40%	47.59%
QST	42 Neutral	C$7.99M	―	-14.23%	―	-37.13%	32.21%

Biorem Inc Corporate Events

Biorem Inc. Achieves Record Financial Performance in 2024

Biorem Inc. reported record revenues and earnings for the fiscal year 2024, with a 49% increase in revenue to $37.4 million and a 36% rise in net earnings to $3.0 million compared to 2023. The company also achieved a record order backlog of $56.1 million, reflecting strong business development efforts and investments in manufacturing processes that enhanced production capacity and reduced costs. Despite challenges such as geopolitical and tariff pressures anticipated in 2025, Biorem remains confident in its ability to navigate these issues due to its diverse supply chain, American-based manufacturing, and robust financial position.

Spark’s Take on TSE:BRM Stock

According to Spark, TipRanks’ AI Analyst, TSE:BRM is a Outperform.

Biorem Inc’s strong financial performance, characterized by significant revenue growth and robust cash flow, is the primary driver of its stock score. The company’s valuation suggests it may be undervalued, adding to its appeal. However, the neutral technical indicators and lack of earnings call or corporate event data slightly temper the overall positive outlook.

To see Spark’s full report on TSE:BRM stock, click here.

BIOREM Inc. Secures $8 Million in New Orders Amid Growing Demand

BIOREM Inc. has announced new orders totaling over $8 million, contributing to an order backlog of $60.5 million. The orders involve the deployment of BIOREM’s advanced air emission abatement technologies across various locations in Asia and the Americas. The company has seen increased demand driven by its new products and services, with a mix of infrastructure and industrial applications forming a significant part of the new orders. Despite potential tariff impacts in North America, BIOREM is well-positioned due to its diverse supply chain and separate divisions in Canada and the US, ensuring resilience against any trade-related challenges.